DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
A Drug Safety Communication requests removal of the suicidal behavior and ideation warning from GLP‑1 receptor agonist medications.
On January 13, 2026 the FDA issued a Drug Safety Communication requesting removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications. Mood changes can still happen for individual reasons: tell your prescriber about new or worsening depression or thoughts of self-harm, as with any medication.